How to Stack SS-31 + MOTS-C (Exact Dosing Protocol)
Your mitochondria are running two separate repair systems right now, and most people trying to support them pick one or the other when the smarter move is running both at the same time for different reasons.
To understand why the stack works, you need the full picture first.
Mitochondria produce energy through a process that happens along their inner membrane, and that membrane has to maintain a very precise structure to work. Over time, oxidative stress damages a fat molecule in that membrane called cardiolipin, which is what holds the electron transport chain proteins in the right geometry. When cardiolipin gets damaged, the whole assembly loosens, electron flow becomes inefficient, and energy output drops. At the same time, mitochondria respond to cellular stress by sending out small signaling proteins called mitochondrial-derived peptides, which travel to the nucleus and adjust gene expression to try to compensate for the damage. Both of those systems, the structural one and the signaling one, can be supported from the outside. That is the whole logic of the stack.
SS-31 is a peptide that concentrates specifically at the inner mitochondrial membrane, binding to cardiolipin directly and stabilizing its structure. MOTS-c is one of those naturally occurring mitochondrial-derived peptides, and when you introduce more of it, it amplifies the signaling cascade that your mitochondria are already trying to run.
They fix different things. That is why combining them makes mechanistic sense.
Start with SS-31 because its pharmacology is unusual in a way that changes how you dose it.
Most peptides work by binding to receptors, and receptors can desensitize when they are continuously activated, which is why cycling protocols exist for many compounds. SS-31 does not bind to a receptor. It binds to cardiolipin, the fat molecule itself, and cardiolipin does not downregulate. There is no feedback signal, no regulatory response, nothing to desensitize. The structural repair just accumulates over time as long as the peptide is present.
This has a direct implication for the half-life math. SS-31 clears plasma in about two hours, which sounds like a problem until you realize the benefit is not in the plasma, it is at the membrane. The peptide concentrates at the inner membrane at roughly five thousand times the plasma concentration, which means even small doses are delivering meaningful amounts exactly where the work happens.
The dose-response data supports this. A comparison trial in heart failure patients testing 4 milligrams against 40 milligrams found no functional advantage at the higher dose. The concentration effect makes the dose-to-benefit curve flatten out earlier than you would expect. Your working range is 1 to 5 milligrams per day, and because the benefit builds structurally over weeks, daily dosing is the right approach. The longest published human trial ran SS-31 continuously for 168 weeks, which is over three years, with progressive improvement and no tolerance documented. The cycling recommendation for SS-31 is precautionary, not mechanistically motivated.
MOTS-c has a completely different pharmacology, and that changes the dosing logic.
Where SS-31 does structural work at the membrane, MOTS-c works through gene expression. It activates something called the AMPK pathway, which is a cellular energy sensor that, when triggered, upregulates mitochondrial biogenesis and improves how efficiently the existing mitochondria run. The downstream effects of that gene expression change persist long after the peptide itself has cleared, because the change is happening at the level of what genes are being read, not at the level of how much peptide is in circulation.
This matters because it means plasma half-life is largely irrelevant to dosing frequency. A study examining maintenance dosing found that three times per week preserved all the benefits of daily administration, because the gene expression effects from each dose overlap with the residual effects of the previous one. You are not trying to maintain a blood level. You are triggering a cascade and giving it time to run.
MOTS-c also improves mitochondrial quality without increasing mitochondrial content, which is a meaningful distinction. More mitochondria is not always better if the new ones are producing the same inefficient, high-ROS output as the damaged ones. MOTS-c appears to improve the function of existing mitochondria and reduce reactive oxygen species output through the same AMPK-dependent mechanism, which means the benefit is efficiency and less oxidative damage, not just volume.
Your working range for MOTS-c is 5 to 15 milligrams per week, administered Monday, Wednesday, Friday.
For the combined protocol, the practical numbers that tend to work across a range of people are 2 milligrams of SS-31 daily and 10 milligrams of MOTS-c per week split across three injections. If you are new to either compound, starting at half those doses for the first two to four weeks gives you a clean baseline to assess tolerance. If you are addressing significant age-related decline where the mitochondrial dysfunction is more established, the upper range of 5 milligrams SS-31 daily and 15 milligrams MOTS-c weekly is supported by the individual compound data.
The honest caveat is that no human trial has tested these two compounds together. The combination logic is built on non-overlapping mechanisms, one structural and one signaling, and on SS-NMN combination data in aged mice that showed additive benefits when a structural repair compound was paired with a metabolic signaling compound. That is the closest published analog to this stack, but it is an analog, not a direct test of this specific combination.
The cycling question deserves a direct answer. For SS-31, the mechanism gives you no reason to cycle. For MOTS-c, your body already produces this peptide endogenously, and unlike testosterone there is no negative feedback loop that would suppress natural production in response to exogenous administration. The animal research gave MOTS-c continuously for the animals' entire remaining lifespan with sustained benefits and no documented downregulation. The 4 to 8 week off-cycle recommendation exists because we do not have long-term human data at these doses, not because the biology suggests you need it.
Most cycling protocols exist to manage receptor desensitization or feedback suppression. When neither of those mechanisms is present, the cycle is a precaution against unknowns, which is a reasonable precaution, but you should know that is what it is.
The deeper point here is that mitochondrial decline is not a single failure. It is structural damage accumulating in the membrane and signaling dysfunction reducing the cell's ability to respond to that damage, and those are two separate problems happening in parallel. Treating them as one problem and picking a single compound is the same mistake as treating a factory's broken machinery and its communication failures as the same issue. They are not.
References
- Thompson WR, et al. A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a mitochondrial cardiomyopathy. Genetics in Medicine. 2024;267:101133. 168-week continuous SS-31 at 40mg daily with progressive improvement and no tolerance. Source
- Butler J, et al. Effects of elamipretide on left ventricular function in patients with heart failure with reduced ejection fraction: The PROGRESS-HF phase 2 trial. Journal of Cardiac Failure. 2020;265:429-437. 4mg vs 40mg comparison: 40mg showed no advantage over 4mg. Source
- Reynolds JC, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12:470. 3x/week maintenance dosing preserved all benefits after daily loading. Source
- Gudiksen A, et al. MOTS-c improves intrinsic muscle mitochondrial bioenergetic health and efficiency in a PGC-1alpha/AMPK-dependent manner. Free Radical Biology and Medicine. 2026;246:682-696. MOTS-C improves mitochondrial quality without increasing content, reduces ROS. Source
- Whitson JA, et al. SS-31 and NMN: Two paths to improve metabolism and function in aged hearts. Aging Cell. 2020;1910:e13213. Closest published combination data: SS-31 + NMN synergy in aged mice. Source
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;213:443-454. Original MOTS-C dosing data: 0.5mg/kg chronic, 5mg/kg acute in mice. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.